Table 5.

Correlation between clinicopathologic factors and p16/pRB status

Parameters	p16 alteration			p16 status			pRB status
	No n = 212 (%)	Yes n = 194 (%)	p-value	Negative n = 31 (%)	Positive n = 375 (%)	p-value	Negative n = 339 (%)	Positive n = 67 (%)	p-value
Age (years)			0.359			0.576			0.452
≤ 50	115 (54.2)	114 (58.8)		16 (51.6)	213 (56.8)		194 (57.2)	35 (52.2)
> 50	97 (45.8)	80 (41.2)		15 (48.4)	162 (43.2)		145 (42.8)	32 (47.8)
Histologic grade			0.449			0.204			0.108
I/II	142 (67.0)	123 (63.4)		17 (54.8)	248 (66.1)		227 (67.0)	38 (56.7)
III	70 (33.0)	71 (36.6)		14 (45.2)	127 (33.9)		112 (33.0)	29 (43.3)
Tumor stage			0.427			0.093			0.894
T1	110 (51.9)	93 (47.9)		11 (35.5)	192 (51.2)		170 (50.1)	33 (49.3)
T2/T3	102 (48.1)	101 (52.1)		20 (64.5)	183 (48.8)		169 (49.9)	34 (50.7)
Nodal metastasis			0.925			0.422			0.944
Absent	131 (61.8)	119 (61.3)		17 (54.8)	233 (62.1)		209 (61.7)	41 (61.2)
Present	81 (38.2)	75 (38.7)		14 (45.2)	142 (37.9)		130 (38.3)	26 (38.8)
ER status			0.187			0.002			0.242
Negative	75 (35.4)	81 (41.8)		20 (64.5)	136 (36.3)		126 (37.2)	30 (44.8)
Positive	137 (64.6)	113 (58.2)		11 (35.5)	239 (63.7)		213 (62.8)	37 (55.2)
PR status			0.237			0.004			0.009
Negative	99 (46.7)	102 (52.6)		23 (74.2)	178 (47.5)		158 (46.6)	43 (64.2)
Positive	113 (53.3)	92 (47.4)		8 (25.8)	197 (52.5)		181 (53.4)	24 (35.8)
HER-2 status			0.418			0.895			0.001
Negative	176 (83.0)	155 (79.9)		25 (80.6)	306 (81.6)		286 (84.4)	45 (67.2)
Positive	36 (17.0)	39 (20.1)		6 (19.4)	69 (18.4)		53 (15.6)	22 (32.8)
Ki-67 LI (%)			0.013			< 0.001			< 0.001
≤ 14	132 (62.3)	97 (50.0)		8 (25.8)	221 (58.9)		207 (61.1)	22 (32.8)
> 14	80 (37.7)	97 (50.0)		23 (74.2)	154 (41.1)		132 (38.9)	45 (67.2)